Condition: Alpha-1 Antitrypsin Deficiency (AATD) · Sponsor: Tessera Therapeutics, Inc.
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
This description comes directly from the study's public registry record.
Tessera Clinical Trials Information · 857-271-4800 · clinicalinfo@tesseratx.com
Always discuss trial participation with your own doctor first.
| Clinical Study Center | Boston, Massachusetts, United States | Recruiting |
| Clinical Study Center | Charleston, South Carolina, United States | Recruiting |
| Clinical Study Center | Seattle, Washington, United States | Recruiting |
| Clinical Study Center | Fitzroy, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07227207